BMEA

BMEA

USD

Biomea Fusion Inc. Common Stock

$2.610+0.140 (5.668%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$2.470

Haut

$2.650

Bas

$2.435

Volume

2.30M

Fondamentaux de l'Entreprise

Capitalisation Boursière

98.1M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.91M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $1.291Actuel $2.610Haut $13.07

Actualités Connexes

GlobeNewswire

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus

Voir plus
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Analyst Upgrades

Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7

Piper Sandler analyst Edward Tenthoff assumes Biomea Fusion with a Overweight rating and announces Price Target of $7.

Voir plus
Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7
Analyst Upgrades

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion with a Buy and maintains $16 price target.

Voir plus
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
GlobeNewswire

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the

Voir plus
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.